A carregar...
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma
Seventy-five percent of lung adenocarcinomas with epidermal growth factor receptor (EGFR) mutations respond to treatment with the tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib; however, drug-resistant tumors eventually emerge. In 60% of cases, resistant tumors carry a secondary mutation...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
The Company of Biologists Limited
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2806903/ https://ncbi.nlm.nih.gov/pubmed/20007486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1242/dmm.003681 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|